Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fluicell ABFRA:5J90 -5.48%61 Gross Margin % is 116.78% as of Mar. 2026, which is 48% above its 10-year median of 78.68. GuruFocus rates FRA:5J90 with a GF Score™ of 61/100 and a GF Value™ of €2.88 (Fairly Valued). The stock has 4 warning signs investors should review. Among 733 Biotechnology companies, Fluicell AB ranks better than 99.32% on this metric.
Gross Margin % is calculated as gross profit divided by its revenue. Fluicell AB's Gross Profit for the
three
months ended in Mar. 2026 was €0.66 Mil. Fluicell AB's Revenue for the
three
months ended in Mar. 2026 was €0.57 Mil. Therefore, Fluicell AB's Gross Margin % for the quarter that ended in Mar. 2026 was 116.78%.
The historical rank and industry rank for Fluicell AB's Gross Margin % or its related term are showing as below:
FRA:5J90'
s Gross Margin % Range Over the Past 10 Years
Min: 44.11 Med: 78.68 Max: 218.79
Current: 152.45
During the past 11 years, the highestGross Margin % of Fluicell AB was 218.79%. The lowest was 44.11%. And the median was 78.68%.
FRA:5J90's Gross Margin % is ranked better than 99.32% of 733
companies
in the Biotechnology industry
Industry Median: 60.91
vs FRA:5J90: 152.45
Fluicell AB had a gross margin of 116.78% for the quarter that ended in Mar. 2026 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for Fluicell AB was 24.80% per year.
Fluicell AB (FRA:5J90) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Fluicell AB had a gross margin of 116.78% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Fluicell AB Gross Margin % Related Terms
Fluicell AB Gross Margin % Historical Data
* Premium members only.
The historical data trend for Fluicell AB's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5J90 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Fluicell AB's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fluicell AB Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fluicell AB's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Fluicell AB's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Fluicell AB (FRA:5J90) has a Gross Margin % of 116.78% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Fluicell AB and its competitors. This is 48% above median its historical median of 78.68. Over the past decade, Fluicell AB's Gross Margin % has ranged from 44.11 to 218.79. According to the industry distribution chart, Fluicell AB ranks #5 out of 733 companies in the Biotechnology industry, placing it in the top 0.7%.
Is Fluicell AB's Gross Margin % too high?
Fluicell AB's current Gross Margin % of 116.78% is 48% above median its 10-year median of 78.68. Over the past 10 years, this metric has ranged from a low of 44.11 to a high of 218.79. The Biotechnology industry median Gross Margin % is 60.91. Fluicell AB's value of 116.78% is 91.7% above this industry median. Based on the distribution chart, Fluicell AB ranks #5 out of 733 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Fluicell AB has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Fluicell AB's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Fluicell AB ranks #5 out of 733 companies for Gross Margin %. This places Fluicell AB in the top 1% of its industry — outperforming the majority of peers. The industry median Gross Margin % is 60.91. Fluicell AB's value of 116.78% is 91.7% above this benchmark. Historically, Fluicell AB's own Gross Margin % has ranged from 44.11 to 218.79 over the past decade. While the company's 10-year median is 78.68 vs. the industry median of 60.91, Fluicell AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fluicell AB's current Gross Margin % of 116.78% is 91.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Fluicell AB and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fluicell AB's current Gross Margin % is 116.78%, which is 48% above median its own 10-year median of 78.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fluicell AB stock overvalued right now?
Based on GuruFocus' analysis, Fluicell AB (FRA:5J90) is currently considered Fairly Valued. The stock's GF Value™ is €2.88, compared to a current price of €2.93 — trading 1.7% above its estimated fair value. The current Gross Margin % is 116.78%, which is 48% above median its 10-year median of 78.68 and 91.7% above the Biotechnology industry median of 60.91. Fluicell AB's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Fluicell AB (FRA:5J90), the current Gross Margin % is 116.78% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fluicell AB (FRA:5J90) Overvalued in 2026?
Based on GuruFocus' analysis, Fluicell AB stock appears to be overvalued.
The current stock price of €2.93 is trading 1.7% above its estimated GF Value™ of €2.88.
GuruFocus considers Fluicell AB to be Fairly Valued.
Key valuation signals for FRA:5J90:
Gross Margin %: 116.78% (48% above median its 10-year median of 78.68)
GF Value™: €2.88 vs. price of €2.93 (1.7% above fair value)
Industry Position: 91.7% above the Biotechnology median (#5 of 733)
No single metric tells the full story. See the FRA:5J90 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fluicell AB is a Swedish life science company that conducts development in regenerative medicine and human tissue-based screening models for drug development, with a particular focus on the areas of type 1 diabetes, cardiac safety screening models, and kidney diseases. The company's platform for the production of human tissue that is based on Fluicell's technology for high-resolution 3D bioprinting, and which enables the creation of tissue-based products for use in drug development and regenerative medicine.
61GF Score
Get the complete analysis for FRA:5J90
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5J90 has been successfully added to your 
